FDA to speed up approvals of generic biologic medicines as Trump targets high drug costs

CNBC October 29, 2025
Annika Kim Constantino

Key Points

– The Food and Drug Administration said it will take steps to speed up the process of developing generic versions of complex biological drugs, in a bid to increase cheaper competition for expensive medicines and lower drug costs for Americans.

– It’s the Trump administration’s latest move to rein in high prescription drug costs in the U.S., and could be a blow to pharmaceutical companies.

– The FDA’s new reforms “will take the five-to-eight year timeframe to bring a biosimilar to market and cut it in half,” said the agency’s commissioner, Marty Makary.

The Food and Drug Administration on Wednesday said it will take steps to speed up the process of developing generic versions of complex biological...

Today's Sponsors

Today's Sponsor